Suraj Konnath George
Overview
Explore the profile of Suraj Konnath George including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
George B, George S, Shi W, Haque A, Shi P, Eskandari G, et al.
J Hematol Oncol
. 2023 Jun;
16(1):61.
PMID: 37312210
No abstract available.
2.
George B, Haque A, Sahu V, Joldoshova A, Singh Y, Quinones J, et al.
Appl Immunohistochem Mol Morphol
. 2022 May;
30(5):333-339.
PMID: 35510772
The introduction of targeted therapy has revolutionized cancer treatment. Nonetheless, for this approach to succeed, it is crucial to identify the targets, particularly when activated, in tumor tissues. Phosphorylation is...
3.
George B, George S, Shi W, Haque A, Shi P, Eskandari G, et al.
J Hematol Oncol
. 2019 Jul;
12(1):80.
PMID: 31340850
Background: Nucleophosmin-anaplastic lymphoma kinase-expressing (NPM-ALK) T cell lymphoma is an aggressive neoplasm. NPM-ALK, an oncogenic tyrosine kinase, plays a critical role in this lymphoma. Recently, selective ALK inhibitors have emerged...
4.
Shi W, George S, George B, Curry C, Murzabdillaeva A, Alkan S, et al.
Mol Oncol
. 2017 May;
11(9):1189-1207.
PMID: 28557340
Nucleophosmin-anaplastic lymphoma kinase-expressing (NPM-ALK ) T-cell lymphoma is an aggressive neoplasm that is more commonly seen in children and young adults. The pathogenesis of NPM-ALK T-cell lymphoma is not completely...
5.
Vishwamitra D, George S, Shi P, Kaseb A, Amin H
Oncotarget
. 2016 Sep;
8(1):1814-1844.
PMID: 27661006
The insulin-like growth factor (IGF) signaling system plays key roles in the establishment and progression of different types of cancer. In agreement with this idea, substantial evidence has shown that...
6.
Mitchell J, Tinkey P, Avritscher R, Van Pelt C, Eskandari G, George S, et al.
Oncology
. 2016 Jun;
91(2):90-100.
PMID: 27305144
Objective: The purpose of this study was to reduce the time to tumor onset in a diethylnitrosamine (DEN)-induced hepatocellular carcinoma (HCC) swine model via partial liver embolization (PLE) and to...
7.
Yang L, Zhang S, George S, Teng R, You X, Xu M, et al.
Oncotarget
. 2015 Apr;
6(17):14953-69.
PMID: 25879451
The T-cell lymphoproliferative neoplasms (T-LPN) are characterized by a poor clinical outcome. Current therapeutics are mostly non-selective and may induce harmful side effects. It has been reported that NOTCH1 activation...
8.
George S, Vishwamitra D, Manshouri R, Shi P, Amin H
Oncotarget
. 2014 Jul;
5(14):5750-63.
PMID: 25026277
NPM-ALK⁺ T-cell anaplastic large-cell lymphoma (ALCL) is an aggressive type of cancer. Standard treatment of NPM-ALK⁺ ALCL is CHOP polychemotherapy. Although patients initially respond favorably to CHOP, resistance, relapse, and...
9.
George S, Tovar-Sepulveda V, Shen S, Jian W, Zhang Y, Hilsenbeck S, et al.
Transl Oncol
. 2013 Jun;
6(3):244-55.
PMID: 23730403
Bladder cancer is the fifth most frequent tumor in men and ninth in women in the United States. Due to a high likelihood of recurrence, effective chemoprevention is a significant...